Available IPD datapackage for study 'A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer'

This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was
designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1
[PD-L1] antibody) in combination with carboplatin plus (+) etoposide compared with treatment
with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC.
Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin +
etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the
induction phase followed by maintenance with atezolizumab or placebo until progressive
disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid
Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD
or symptomatic deterioration.